Blockade of the immune-inhibitory PD-L1–PD-1 pathway has shown remarkable efficacy in patients with advanced NSCLC, melanoma, renal-cell cancer, and Hodgkin’s lymphoma including upon failure to several lines of therapy [13,25-27]. Here, CD274 is linked to non-small cell lung carcinoma.